Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors

被引：0

作者：

De Miguel, M. ^{[1
]}

Landa Magdalena, A. ^{[2
]}

Moreno Garcia, V. ^{[3
]}

Gambardella, V. ^{[4
]}

Menis, J. ^{[5
]}

Daniele, G. ^{[6
]}

El-Khoueiry, A. B. ^{[7
]}

Spira, A. I. ^{[8
]}

Gravina, A. ^{[9
,10
]}

Olszanski, A. J. ^{[11
]}

Rapaic, O. ^{[12
]}

Li, J. ^{[13
]}

Poullain, H. ^{[14
]}

Margall, G. ^{[14
]}

Wong, G. ^{[15
]}

Hedrich, W. ^{[16
]}

Pollard, J. Russella ^{[15
]}

Gan, J. ^{[17
]}

Shi, X. ^{[18
]}

Andtbacka, R. H. I. ^{[19
]}

机构：

[1] Hosp Univ HM Sanchinarro, CIOCC Ctr Integral Oncol Clara Campal, Early Phase Clin Trial Unit, Madrid, Spain

[2] Clin Univ Navarra, Dept Med Oncol, Madrid, Spain

[3] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain

[4] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[5] AOU Integrata Verona Osped Borgo Roma, Med Oncol, Verona, Italy

[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Phase Unit 1, Rome, Italy

[7] USC Univ Southern Calif, Keck Sch Med, Med Oncol Div, Los Angeles, CA USA

[8] Virginia Canc Specialist, Res Dept, Fairfax, VA USA

[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Dipartimento Ric Traslaz, Naples, Italy

[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Serv Percorsi Oncol, Naples, Italy

[11] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA

[12] HiFiBiO Inc, Clin Operat, Cambridge, MA USA

[13] HiFiBiO Therapeut Inc, Dis Biol, Cambridge, MA USA

[14] HiFiBio SAS, Translat Med, Paris, France

[15] HiFiBiO Therapeut Inc, Translat Med, Cambridge, MA USA

[16] HiFiBiO Therapeut Inc, Clin Pharmacol, Cambridge, MA USA

[17] HiFiBiO Therapeut Inc, Res, Cambridge, MA USA

[18] HiFiBiO Therapeut, Clin Dev, Shanghai, Peoples R China

[19] HiFiBiO Therapeut Inc, Clin Dev, Cambridge, MA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1065

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1006P

引用

页码：S684 / S684

页数：1

共 50 条

[1] Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Perez, D. Roda
Zugazagoitia, J.
Garralda, E.
Spira, A. I.
El-Khoueiry, A. B.
Zhao, Y.
Oppelt, P.
Lin, X.
Xie, S.
Chen, M.
Gan, J.
Wong, G.
Pollard, J. Russella
Hedrich, W.
Pallante, J.
Adrian, F.
Schweizer, L.
Shi, X.
Andtbacka, R. H. I.
ANNALS OF ONCOLOGY, 2024, 35 : S686 - S686
[2] Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors
Roda, Desamparados
Zugazagoitia, Jon
Garralda, Elena
Spira, Alexander I.
El-Khoueiry, Anthony B.
Babiker, Hani M.
Oppelt, Peter John
Lin, Xi
Xie, Shaozhen
Chen, Margaret E.
Gan, Jinping
Wong, Gabrielle
Pollard, Jack Russella
Hedrich, William
Pallante, John
Hatzis, Christos
Andtbacka, Robert H.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
Ganju, Vinod
Cooper, Adam
Gao, Bo
Wilkinson, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
Ganju, Vinod
Cooper, Adam
Gao, Bo
Wilkinson, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors
Naing, A.
Goel, S.
Curti, B.
Weise, A.
Eder, J. P.
Marshall, S.
Morehouse, C.
Li, X.
Karakunnel, J. J.
Infante, J.
ANNALS OF ONCOLOGY, 2016, 27
[6] A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors
Deva, Sanjeev
Zhou, Caicun
Bishnoi, Sarwan K.
Lau, Peter Kar Han
Tran, Ben
Ba, Yi
Galsky, Matt D.
Wang, Yongsheng
Zhang, Yanqiao
Luo, Suxia
Chang, Victoria
Yu, Cunjing
Zhang, Teresa
Zhang, Heather
Ma, Jiafang
Naicker, Kirsha May
Yap, Timothy A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
Coward, Jermaine
Ben Markman
Nagrial, Adnan
Abed, Afaf
Walpole, Imogen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
Coward, Jermaine
Abed, Afaf
Nagrial, Adnan
Markman, Ben
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
Zhou, Cai
He, Yayi
Ren, Shengxiang
Li, Wei
Zhu, Jun
Yu, Jia
Wang, Lei
Xiong, Anwen
Xu, Nong
Mao, Chenyu
Pan, Beiqing
Liu, Ying
Zhou, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
Deva, S.
Lee, J-S.
Lin, C-C.
Yen, C-J.
Millward, M.
Chao, Y.
Keam, B.
Jameson, M.
Hou, M-M.
Kang, Y-K.
Markman, B.
Lu, C-H.
Rau, K-M.
Lee, K-H.
Horvath, L.
Friedlander, M.
Hill, A.
Wu, J.
Hou, J.
Desai, J.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →